(Total Views: 617)
Posted On: 05/16/2024 1:51:18 PM
Post# of 155865
Bravo, Dr. J …. I think we are all extremely impressed by what Dr. J did since he became CyDy’s CEO.
Please excuse my ignorance. After his last letter to the shareholders this morning, I wonder why suddenly we have this priority of a Phase II study of Leronlimab in patients with relapsed/refractory microsatellite stable Colorectal Cancer/CRC.
Then, if you check this article below on using immunotherapies for CRC, you can tell that so many monoclonal antibodies/MABs are being used already (See Tables 3 & 4) except Leronlimab.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10963412/
But the CRC market isn’t that big if you check the link below.
https://colorectalcancer.org/article/acs-rele...rQEALw_wcB
Just a question here and no intention to be a stock pumper. Is it because we have potential partners, whom they want to see what Leronlimab can do in their combined trials after a Phase II study?
Please excuse my ignorance. After his last letter to the shareholders this morning, I wonder why suddenly we have this priority of a Phase II study of Leronlimab in patients with relapsed/refractory microsatellite stable Colorectal Cancer/CRC.
Then, if you check this article below on using immunotherapies for CRC, you can tell that so many monoclonal antibodies/MABs are being used already (See Tables 3 & 4) except Leronlimab.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10963412/
But the CRC market isn’t that big if you check the link below.
https://colorectalcancer.org/article/acs-rele...rQEALw_wcB
Just a question here and no intention to be a stock pumper. Is it because we have potential partners, whom they want to see what Leronlimab can do in their combined trials after a Phase II study?
(3)
(0)
